In general, studies are powered to demonstrate effect against placebo, and not powered to investigate differences between dose levels.
No serious adverse events were observed but the study was not sufficiently powered to demonstrate complete safety.
The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast cancer.
It was not powered to demonstrate superiority of the individual doses of lasmiditan to placebo (see Fig. 1).
Although not powered to demonstrate statistical significance, mortality, PICU and hospital length of stay, duration of mechanical ventilation, dose and duration of inotropic support were similar.
We included physician gestalt because this is frequently used in the clinical setting to assess dehydration; however, the study was not specifically powered to demonstrate the superiority of ultrasound over physician gestalt.
Additionally, it is important to note that the ORATORIO trial was not powered to demonstrate a difference in the subgroup analysis of efficacy between patients with and without GEL at baseline.
The study was preemptively dimensioned and powered to demonstrate 30 % reduction in TI delay for the patients with difficult laryngoscopy as attested by the low percentage of glottis inlet visible (POGO score) of below 30%% (Ref).
It should be noted that the present study was sufficiently powered to demonstrate effect based on previous study [41], however the low exposures of BGC20-1531 in 3 out of 8 volunteers may have contributed to the negative outcome in this study.
None of the trials was individually powered to demonstrate an effect on severe malaria or all-cause mortality.
Cure rates for the 14 day PQ appear slightly higher than for 8 week PQ regimens (AOR 3.8 [95%CI–0.4-36.7] p = 0.3), however the study was insufficiently powered to demonstrate equivalence or superiority.
